An observational study in Financial Benefit, Colorectal Cancer and Surgery, sponsored by Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori. Status unknown at 9 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-11.
Sponsored by Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori · Observational
Focus of this project is to evaluate the possible financial benefit resulting from an optimization of surgical outcomes throughout a collaborative and systematic auditing activity.The primary objective of this analysis is to assess the employed resources by National Health System related to surgical activities for primary colorectal cancer during a collaborative and systematic auditing activity in 8 Surgical Units of Emilia-Romagna
Focus of this project is to evaluate the possible financial benefit resulting from an optimization of surgical outcomes throughout a collaborative and systematic auditing activity.
The primary objective of this analysis is to assess the employed resources by National Health System related to surgical activities for primary colorectal cancer during a collaborative and systematic auditing activity in 8 Surgical Units of Emilia-Romagna. A project team composed by experts in colorectal cancer care will be created with the task of identifying the needed resources to allocate to the project and the set of administrative, economic and performance indicators to be measured during the project. A friendly, time-preserving dataset that includes all the items to be collected to measure established indicators will be developed. An analysis on costs and performance indicators will be conducted on colorectal procedures performed between 1 January 2019 and 31 December 2019 within the participating centers. From the second year auditing activity will be implemented among institutions of Emilia-Romagna. Analysis results obtained from the first year of collecting data will be used as a starting feedback report to implement the auditing activity dedicated to colorectal cancer. During the whole second year monthly feedback reports will be drafted and used for monitoring costs and performances outcomes of colorectal surgery procedures between 1 January 2020 and 31 December 2020.
At the end of the second year a final analysis will be performed to compare resources employed for colorectal cancer surgery between the first and second year. Economical and performance data will be collected.
Focusing on costs, the main sources to be used are administrative databases. Full in-hospital costs will be collected for each patient for the time interval between the day of admission for surgery and the following post-operative 90-days. The Diagnosis Related Groups (DRG) standardized payments will be used to calculate inpatient costs.
Another source for cost and performance information is the clinical chart (paper or electronic) in all its parts. The investigators will focus primarily on set of data, that potentially could contribute to define the cost of care on basis of post-operative pathway. Key performance indicators common to both colon and rectal surgery or specific for one of the two surgical procedure will be considered.
5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.
This study's planned enrollment of 1,400 is above the median of 250 across 1,226 observational studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori is the lead sponsor of 25 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All consecutive patients diagnosed with malignant colorectal cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period will be collected
Exclusion Criteria:
patients diagnosed with colon cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
Procedure: all colorectal cancer surgical procedures
patients diagnosed with rectal cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
Procedure: all colorectal cancer surgical procedures
colorectal cancer surgical procedures
health care resources utilization (HCRU)
To identify the resources delivered to surgical patients. Resource are retrieved from administrative database.
Time frame: 90 day post surgery
Cost relate to HCRU
To identify the significant cost drivers for the surgical management of colorectal cancer patients and to verify the impact on economic resource consumption of the systematic auditing activities. Costs are retrieved from adminatrative database.
Time frame: 90 day post-surgery
% of patients with post-operative complications
To assess the frequency of post-operative complications, unplanned re-interventions and re-admission. This outcome is measured from data collected in Case Report Form (CRF)
Time frame: 180 days post surgery
Rate of mortality at 30 days
To assess mortality rates at 30 days. This outcome is measured from data collected in CRF and from administrative database.
Time frame: 30 days post surgery
Rate of mortality at 90 days
To assess mortality rates at 90 days. This outcome is measured from data collected in CRF and from administrative database.
Time frame: 90 days post surgery
Rate of mortality at 180 days
To assess mortality rates at 180 days. This outcome is measured from data collected in CRF and from administrative database.
Time frame: 180 days post surgery
% of patients discussed in Multidisciplinary team meeting
To assess the number of patient discussed within a multidisciplinary team meeting before colon rectal surgery. This outcome is measured from data collected in CRF.
Time frame: 180 days post surgery
% of patients who underwent minimally invasive resection
To assess the number of minimally invasive resections. This outcome is measured from data collected in CRF.
Time frame: 180 day post surgery
Conversion rate
to assess the rate of conversion surgery. This outcome is measured from data collected in CRF.
Time frame: 180 day post surgery
% of patients with adequacy of lymph node sampling
To assess adequate intraoperative lymph node sampling of colorectal surgery. This outcome will be measured from data collected in CRF.
Time frame: 180 days post surgery
Rate of anastomosis
To assess the rate of anastomosis after low anterior resection vs terminal colostomy. This outcome will be measured from relative data collected in CRF.
Time frame: 180 days post surgery
Rate of Miles procedure
to assess the rate of Miles procedures in rectal cancer patients. This outcome is measured from data collected in CRF.
Time frame: 180 days post surgery
Quality of Total Mesorectal Excision: rate of positive Circumferential Resection Margin in patients with rectal cancer.
To assess the rate of positive Circumferential Resection Margin in rectal cancer patient. This outcome will be measured from data collected in CRF.
Time frame: 180 days post surgery
Rate of loop ileostomy in patients with rectal cancer
To assess the rate of loop ileostomy after rectal cancer resection. This outcome is measured from data collected in CRF.
Time frame: 180 days post surgery
% of patients with rectal cancer who underwent preoperative chemo-radiation therapy
To assess the appropriateness of preoperative chemo-radiation therapy in rectal cancer patients. This outcome is measured from data collected in CRF.
Time frame: 180 days post surgery
Rate of preoperative chemo-radiation therapy in patients with rectal cancer
To assess the rate of preoperative chemo-radiation therapy in rectal cancer patients. This outcome is measured from data collected in CRF.
Time frame: 180 days post surgery
Plan to share: No
This study is status unknown, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori